71 related articles for article (PubMed ID: 21896307)
1. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Bajo AM; Prieto JC
Mol Cell Endocrinol; 2012 Jan; 348(1):241-6. PubMed ID: 21896307
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ
Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.
Collado B; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2006 Apr; 249(1-2):116-22. PubMed ID: 16563610
[TBL] [Abstract][Full Text] [Related]
7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
9. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
10. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
11. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
12. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells.
Ligęza J; Ligęza J; Klein A
Acta Biochim Pol; 2011; 58(3):391-6. PubMed ID: 21887406
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
15. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Maity A; Pore N; Lee J; Solomon D; O'Rourke DM
Cancer Res; 2000 Oct; 60(20):5879-86. PubMed ID: 11059786
[TBL] [Abstract][Full Text] [Related]
19. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.
Contessa JN; Abell A; Valerie K; Lin PS; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):851-8. PubMed ID: 16751066
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.
Collado B; Gutiérrez-Cañas I; Rodríguez-Henche N; Prieto JC; Carmena MJ
Regul Pept; 2004 Jun; 119(1-2):69-75. PubMed ID: 15093699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
